Verrica Pharmaceuticals Reports Strong YCANTH Demand but Wider Losses — Verrica Pharmaceuticals Inc.

Event summary

YCANTH dispensed applicator units grew 28.3% sequentially and 46.1% year-over-year to 19,626 in Q2 2026.
Total revenue reached $5.9 million, with U.S. YCANTH net product revenue up 18.7% quarterly and 12.3% annually.
Net loss widened to $13.2 million (GAAP) or $0.62 per share, compared to a net income of $0.2 million in Q2 2025.
New credit facility for up to $27.5 million with Paul B. Manning extends cash runway into 2028.

The big picture

Verrica Pharmaceuticals is navigating a period of strong commercial traction for YCANTH, its flagship product for molluscum treatment, while managing significant operational costs. The company's strategic focus on expanding into common warts and basal cell carcinoma markets positions it within the competitive dermatology sector, where pipeline advancements and financial flexibility will be critical to long-term success.

What we're watching

Commercial Momentum: Whether Verrica can sustain YCANTH's accelerating demand and expand its market share in molluscum treatment.
Pipeline Progress: The pace at which the Phase 3 program for common warts advances, with topline data expected mid-2027.
Financial Flexibility: How the new credit facility will support Verrica's operations and pipeline development amid widening losses.